These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 19200455)
1. Molecular perspectives on the non-responder phenomenon. Jackson DB Drug Discov Today; 2009 Apr; 14(7-8):373-9. PubMed ID: 19200455 [TBL] [Abstract][Full Text] [Related]
2. Clinical and economic impact of the nonresponder phenomenon--implications for systems based discovery. Jackson DB Drug Discov Today; 2009 Apr; 14(7-8):380-5. PubMed ID: 19200855 [TBL] [Abstract][Full Text] [Related]
3. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026 [TBL] [Abstract][Full Text] [Related]
4. Molecular-targeted therapies: lessons from years of clinical development. Rosa DD; Ismael G; Lago LD; Awada A Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917 [TBL] [Abstract][Full Text] [Related]
5. [Molecular targeted therapy for cancer]. Sone S; Kuramoto T; Sato S; Mitsuhashi A; Kakiuchi S; Goto H; Tada H; Nishioka Y Nihon Rinsho; 2010 Jun; 68(6):997-1006. PubMed ID: 20535947 [TBL] [Abstract][Full Text] [Related]
6. The future of targeted therapies in ovarian cancer. Banerjee S; Gore M Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450 [TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology guidance statement: the cost of cancer care. Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE; J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533 [TBL] [Abstract][Full Text] [Related]
8. Clinical cancer research 2001: new agents and therapies. Verweij J; de Vries EG Drug Resist Updat; 2001 Aug; 4(4):217-23. PubMed ID: 11991676 [No Abstract] [Full Text] [Related]
9. Somatic pharmacogenomics in cancer. Ikediobi ON Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398 [TBL] [Abstract][Full Text] [Related]
11. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Moreno-Aspitia A; Perez EA Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124 [TBL] [Abstract][Full Text] [Related]
12. [Front-line drug discovery system for cancer]. Mizukami T Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393 [TBL] [Abstract][Full Text] [Related]
13. The epothilones: how pharmacology relates to clinical utility. Michaud LB Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389 [TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine. Picker A; Jackson DB Expert Rev Mol Diagn; 2011 Jul; 11(6):567-77. PubMed ID: 21745011 [TBL] [Abstract][Full Text] [Related]
15. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC. Hirsch FR Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291 [TBL] [Abstract][Full Text] [Related]
16. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine. Winquist RJ; Boucher DM; Wood M; Furey BF Biochem Pharmacol; 2009 Aug; 78(4):326-34. PubMed ID: 19539800 [TBL] [Abstract][Full Text] [Related]